Kalnik Matthew W. 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 5, 2010
Insider Transaction Report
Form 4
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
- Award
Common Stock
2010-04-01+24,000→ 53,650.104 total - Sale
Common Stock
2010-04-01$5.48/sh−400$2,193→ 53,000.104 total - Sale
Common Stock
2010-04-01$5.49/sh−1,300$7,131→ 51,700.104 total - Will/Inheritance
Common Stock
2010-04-01$5.49/sh−2,100$11,529→ 49,600.104 total - Award
Stock Option (Right to Buy)
2010-04-01+60,000→ 60,000 totalExercise: $5.49Exp: 2017-04-01→ Common Stock (60,000 underlying) - Sale
Common Stock
2010-04-01$5.48/sh−250$1,370→ 53,400.104 total
Footnotes (3)
- [F1]Restricted Stock which vests in four equal annual installments beginning on April 1, 2011.
- [F2]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
- [F3]This Option will become exercisable in four equal annual installments beginning on April 1, 2011.